Skip to content

Epidemiology and burden

TL;DR — MDD is common, recurrent, disabling, and unequally treated. In a nationally representative US study, lifetime DSM-5 prevalence was 20.6% and 12-month prevalence 10.4% (Hasin 2018, PMID 29450462); global estimates vary with instrument and case definition. GBD 2019 attributed 125.3 million DALYs to mental disorders, with depressive disorders among the largest components, while direct mortality is substantially undercounted by disability-only attribution (GBD 2019, PMID 35026139). US economic burden reached $326.2 billion in 2018, up 37.9% from 2010 in constant dollars (Greenberg 2021, PMID 33950419). Across 21 countries, only a minority of people meeting MDD criteria received minimally adequate care (Thornicroft 2017, PMID 27908899).

Core estimates

Metric Estimate Population/method Source
Lifetime MDD prevalence 20.6% US adults, DSM-5 structured interview, NESARC-III Hasin 2018, PMID 29450462
12-month MDD prevalence 10.4% US adults, same study Hasin 2018, PMID 29450462
Mental-disorder DALYs, 2019 125.3 million; 4.9% of all DALYs GBD modeled estimates, 204 countries/territories GBD 2019, PMID 35026139
Age-standardized mental-disorder DALY rate 1,581 to 1,566 per 100,000, 1990–2019 GBD comparative time series GBD 2019, PMID 35026139
US MDD economic burden, 2018 $326.2 billion claims, workplace, suicide-related costs; 2020 dollars Greenberg 2021, PMID 33950419
Increase in US burden, 2010–2018 37.9% inflation-adjusted comparison Greenberg 2021, PMID 33950419

These figures are not interchangeable. Survey prevalence depends on recall period, diagnostic interview, impairment threshold, inclusion of bereavement, age range, and whether bipolar cases are excluded. Administrative data capture treated disease; screening tools capture symptoms, not necessarily MDD. Systematic review therefore finds wide geographic and methodological variation rather than one universal prevalence (Gutiérrez-Rojas 2020, PMID 32756809).

Distribution and inequality

In NESARC-III, 12-month MDD odds were higher in women, younger adults, and lower-income groups; men had approximately half the odds, people aged 18–29 had threefold odds relative to older reference groups, and low-income adults had about 1.7-fold odds (Hasin 2018, PMID 29450462). These are associations, not immutable biological effects: exposure, recognition, reporting, survival, and access all contribute.

Axis Recurrent finding Interpretation caution
Sex/gender Diagnosed prevalence higher in women Help-seeking, violence exposure, reproductive events, and measurement may contribute
Age High incidence in adolescence/young adulthood; substantial late-life disease First late-life episode requires broader medical differential
Income Higher prevalence and impairment at lower income Bidirectional causation: disadvantage raises risk; illness reduces earning
Conflict/displacement Elevated symptom burden Screening prevalence should not be equated automatically with MDD
Medical comorbidity Higher depression prevalence and worse outcomes Shared biology, treatment effects, disability, and ascertainment interact

Course and recurrence

Cross-sectional prevalence understates burden because MDD is episodic and often recurrent. Time ill is concentrated among people with chronic or recurrent courses, while many first episodes remit. Treatment-response studies should not be read as natural-history cohorts: entry criteria, active management, and attrition reshape observed course.

The transition to treatment-resistant depression (TRD) is definition-dependent. A US claims analysis estimated substantial national prevalence and burden, but claims algorithms cannot confirm dose adequacy, adherence, diagnosis, or whether apparent failure reflected intolerance (Zhdanava 2021, PMID 33989464). TRD is therefore both an epidemiologic state and a measurement problem.

Disability and quality of life

GBD attributes mental-disorder burden predominantly to years lived with disability, with almost no direct years of life lost assigned to the disorders themselves (GBD 2019, PMID 35026139). That convention improves comparability but obscures pathways through suicide, cardiovascular disease, substance use, and health-care disparities. Meta-analysis across mental disorders found roughly doubled all-cause mortality (Walker 2015, PMID 25671328); this estimate is broader than MDD and should not be imported as an MDD-specific causal effect.

Functional burden spans paid work, education, caregiving, relationships, cognition, and self-care. In economic models, presenteeism and absenteeism are major cost components; direct treatment spending is only part of total burden (Greenberg 2021, PMID 33950419). The 2019 update confirms that the US burden remained high beyond the earlier 2010–2018 comparison (Greenberg 2023, PMID 37518849).

Treatment gap

The World Mental Health Surveys examined both contact and adequacy. Across 21 countries, a minority of people with 12-month MDD received minimally adequate treatment, with marked income-country gradients (Thornicroft 2017, PMID 27908899). “Any contact” is not adequate care: dose, duration, follow-up, psychotherapy exposure, and continuity matter.

Gap What is missed Consequence
Recognition gap Symptoms never identified or disclosed No entry to care
Access gap Cost, distance, wait, language, stigma Delayed or absent treatment
Quality gap Inadequate dose/duration or unsupported psychotherapy Contact without effective care
Continuity gap Early dropout, fragmented transitions Relapse and apparent resistance
Specialty gap Complex, psychotic, suicidal, or resistant illness lacks escalation High-risk disease managed below needed intensity

Measurement-based care improved outcomes in an RCT (Guo 2015, PMID 26315978), but implementation requires systems capable of reassessment and timely change; a scale alone does not close access gaps.

Economic burden: what the headline includes

Greenberg and colleagues estimated $326.2 billion for US adults with MDD in 2018, representing a 37.9% inflation-adjusted increase from 2010 (Greenberg 2021, PMID 33950419). The model includes direct medical and pharmaceutical costs, workplace costs, and suicide-related mortality. Because attribution uses matched claims and modeled components, it is not a cash ledger and should not be transferred to other health systems without adjustment.

Component Typical inputs Main uncertainty
Direct inpatient, outpatient, emergency, pharmacy comorbidity attribution
Workplace absenteeism, presenteeism, disability employer and labor-force coverage
Mortality lost earnings associated with suicide causal attribution and valuation method
Informal burden unpaid care, family effects often omitted

Pandemic and temporal interpretation

Time-series analyses show changing global depression burden, but estimates combine evolving data availability with real shocks (Liu 2024, PMID 38811645). Comparisons across GBD releases can change because methods and source data are revised. The correct unit of comparison is a harmonized analysis within one release, not two headline totals from different releases.

Estimates by population and ascertainment

Population Estimate or contrast Ascertainment caveat
Older adults globally Meta-analysis found substantial between-study variation in late-life MDD prevalence Institutionalization, cognitive exclusions, and interview choice affect estimates (Abdoli 2022, PMID 34742925)
Nursing-home residents without dementia Major mood and psychotic disorders were represented in institutional samples Excluding dementia improves specificity but limits generalizability (Fornaro 2020, PMID 30864533)
LGBTQ+ samples Global meta-analysis found high MDD prevalence with regional and methodological heterogeneity Convenience recruitment and minority-stress exposure complicate comparison (Cai 2024, PMID 38795782)
Perinatal period Meta-regression documented substantial prevalence/incidence heterogeneity Antenatal, postpartum, point, and period estimates are not interchangeable (Woody 2017, PMID 28531848)
Postpartum diagnostic interviews Interview-only synthesis differed from screening-positive prevalence Screening prevalence should not be relabeled diagnosed MDD (Bai 2023, PMID 40224605)
Adolescents Global synthesis separated diagnosed depression from elevated symptoms Combining them inflates apparent disorder prevalence (Shorey 2022, PMID 34569066)
Older people in LMICs Meta-analysis found wide geographic and instrument variation Sparse country coverage makes one pooled value misleading (Edwards 2023, PMID 36681304)

Antenatal depression synthesis across 173 studies estimated 20.7% (95% CI 19.4–21.9%), but mixed instruments and settings mean this is not diagnostic-interview MDD prevalence (Yin 2021, PMID 33176244). Ascertainment is therefore a first-order epidemiologic variable.

Course beyond the prevalence snapshot

Complete durable recovery was less common than endpoint-only studies imply because residual symptoms, recurrence, and diagnostic transitions accumulate (Verduijn 2017, PMID 29228943). Earlier modeling showed that duration thresholds and cross-sectional subtypes fail to capture fluctuating illness structure (Judd 2000, PMID 10721877).

Subthreshold depression predicts transitions into disorder and persistence, so threshold prevalence understates near-term risk (Tuithof 2018, PMID 30130686). Machine-learning work in a Brazilian occupational cohort predicted cases, incidence, and chronicity, but transportability and calibration determine population-health utility (Librenza-Garcia 2021, PMID 32493535).

Treatment coverage and implementation

Evidence source Quantity addressed What remains unresolved
Global treatment-rate meta-analysis Any pharmacologic or behavioral treatment “Any treatment” does not establish dose, fidelity, continuity, or response (Mekonen 2021, PMID 34665135)
Bayesian meta-regression, 84 countries MDD coverage from 2000–2019 Country data are uneven; modeled uncertainty should accompany ranks (Moitra 2022, PMID 35167593)
21-country analysis Minimally adequate treatment Adequacy definitions omit patient-defined acceptability and function (Thornicroft 2017, PMID 27908899)
Task-shared psychotherapy IPD meta-analysis Nonspecialist delivery in LMICs Scale-up must preserve supervision, fidelity, and equitable reach (Karyotaki 2022, PMID 35319740)

Coverage is inadequate, yet delivery can be redistributed beyond specialists. The unresolved question is how much effectiveness survives the move from funded trials to routine systems.

Burden revisions and shocks

GBD 2021 quantified incidence, prevalence, YLDs, DALYs, and healthy life expectancy for 371 conditions; releases should not be spliced because new data and modeling rewrite historical series (GBD 2021 Diseases and Injuries Collaborators 2024, PMID 38642570). GBD 2023 provides another internally consistent mental-disorder series, not a directly additive estimate (GBD 2023 Mental Disorder Collaborators 2026, PMID 42167272).

The COVID-19 analysis estimated a marked 2020 increase in depressive and anxiety disorders across 204 countries and territories, with larger effects among women and younger people (COVID-19 Mental Disorders Collaborators 2021, PMID 34634250). It shows burden responding to social disruption; it does not identify one individual-level cause.

Epidemiologic controversies

Question Position A Position B
Is MDD becoming more common? Pandemic modeling shows a real 2020 increase (PMID 34634250) Longer trends depend on recognition, instruments, and revisions
Should screening prevalence guide services? It captures distress and near-threshold need It overstates diagnosed MDD if accuracy and base rates are ignored (PMID 40224605)
Is the treatment gap mainly scarcity? Specialist supply and financing are central Task-sharing works, but fidelity and reach remain constraints (PMID 35319740)
Does remission end burden? Acute remission is meaningful Residual symptoms and functional lag make durable recovery stricter (PMID 29228943)

Open questions

  • How much prevalence variation across countries is real versus generated by instruments, thresholds, and cultural expression (Gutiérrez-Rojas 2020, PMID 32756809)?
  • What fraction of the treatment gap is access versus inadequate treatment after contact (Thornicroft 2017, PMID 27908899)?
  • Can burden models assign mortality pathways without double counting suicide and medical comorbidity (Walker 2015, PMID 25671328; GBD 2019, PMID 35026139)?
  • Which operational TRD definition yields a stable population estimate across claims, surveys, and clinical records (Zhdanava 2021, PMID 33989464)?

References

  1. Hasin DS, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018. PMID 29450462
  2. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019. Lancet Psychiatry. 2022. PMID 35026139
  3. Gutiérrez-Rojas L, et al. Prevalence and correlates of major depressive disorder: a systematic review. Revista Brasileira de Psiquiatria. 2020. PMID 32756809
  4. Greenberg PE, et al. The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018). PharmacoEconomics. 2021. PMID 33950419
  5. Greenberg P, et al. The Economic Burden of Adults with Major Depressive Disorder in the United States (2019). Advances in Therapy. 2023. PMID 37518849
  6. Thornicroft G, et al. Undertreatment of people with major depressive disorder in 21 countries. British Journal of Psychiatry. 2017. PMID 27908899
  7. Zhdanava M, et al. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. Journal of Clinical Psychiatry. 2021. PMID 33989464
  8. Walker ER, et al. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015. PMID 25671328
  9. Guo T, et al. Measurement-Based Care Versus Standard Care for Major Depression. American Journal of Psychiatry. 2015. PMID 26315978
  10. Liu J, et al. Temporal and spatial trend analysis of all-cause depression burden based on Global Burden of Disease 2019. Scientific Reports. 2024. PMID 38811645
  11. Abdoli N, et al. Global prevalence of MDD among older people. Neuroscience and Biobehavioral Reviews. 2022;132:1067-1073. PMID 34742925
  12. Cai H, et al. Global prevalence of MDD in LGBTQ+ samples. Journal of Affective Disorders. 2024;360:249-258. PMID 38795782
  13. Woody CA, et al. Prevalence and incidence of perinatal depression. Journal of Affective Disorders. 2017;219:86-92. PMID 28531848
  14. Fornaro M, et al. Major psychiatric disorders among nursing-home residents without dementia. British Journal of Psychiatry. 2020;216:6-15. PMID 30864533
  15. Verduijn J, et al. Reconsidering the prognosis of MDD. BMC Medicine. 2017;15:215. PMID 29228943
  16. COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 2020. Lancet. 2021;398:1700-1712. PMID 34634250
  17. Mekonen T, et al. Global treatment rates for depression. Journal of Affective Disorders. 2021;295:1234-1242. PMID 34665135
  18. Moitra M, et al. Global gap in MDD treatment coverage, 2000–2019. PLoS Medicine. 2022;19:e1003901. PMID 35167593
  19. Karyotaki E, et al. Task-shared psychological interventions in LMICs. JAMA Psychiatry. 2022;79:430-443. PMID 35319740
  20. GBD 2021 Diseases and Injuries Collaborators. Global burden of 371 diseases and injuries, 1990–2021. Lancet. 2024;403:2133-2161. PMID 38642570
  21. Shorey S, et al. Global prevalence of depression among adolescents. British Journal of Clinical Psychology. 2022;61:287-305. PMID 34569066
  22. Bai Y, et al. Postpartum depression prevalence based on diagnostic interviews. Depression and Anxiety. 2023;2023:8403222. PMID 40224605
  23. Yin X, et al. Prevalence and factors associated with antenatal depression. Clinical Psychology Review. 2021;83:101932. PMID 33176244
  24. Edwards N, et al. Depression and anxiety in older people in LMICs. Journal of Affective Disorders. 2023;325:656-674. PMID 36681304
  25. Librenza-Garcia D, et al. Prediction of depression incidence and chronicity in ELSA-Brasil. Psychological Medicine. 2021;51:2895-2903. PMID 32493535
  26. Judd LL, et al. Longitudinal structure of depressive illness. Pharmacopsychiatry. 2000;33:3-7. PMID 10721877
  27. Tuithof M, et al. Course of subthreshold depression into depressive disorder. Journal of Affective Disorders. 2018;241:206-215. PMID 30130686
  28. GBD 2023 Mental Disorder Collaborators. Updated trends in global mental-disorder burden, 1990–2023. Lancet. 2026;407:2040-2064. PMID 42167272